For over three decades, Taj Pharma Limited has remained at the forefront of pharmaceutical manufacturing, delivering quality-driven, affordable, and reliable healthcare solutions to domestic and international markets. As a globally recognized generic pharma manufacturer in India, we have consistently aligned our operations with the evolving expectations of regulators, healthcare professionals, and international partners. Our journey of more than 30+ years reflects unwavering commitment, scientific excellence, and manufacturing precision that today serves patients across 85+ countries worldwide.
We are proud to present our exclusive and professionally recommended product portfolio, meticulously developed to address specialized therapeutic needs while maintaining the highest standards of safety, efficacy, and compliance. As an experienced CMO and CDMO partner, we support pharmaceutical companies, brand owners, and global distributors with scalable, compliant, and cost-efficient solutions.
About Taj Pharma Limited – Excellence Backed by Experience
Taj Pharma Limited is a fully integrated pharmaceutical organization with deep-rooted expertise in generic drug manufacturing, contract manufacturing, and contract development services. Our extensive international footprint, combined with regulatory-approved manufacturing infrastructure, positions us as a preferred pharmaceutical manufacturing partner from India.
Our operations are driven by robust quality systems, continuous process improvement, and strict adherence to global regulatory norms. With US-FDA, UK-MHRA, EU-GMP, and WHO-GMP compliant facilities, we ensure that every product manufactured under our name or partnership meets the most stringent international benchmarks.
| Sr. No. | Product Name | TAJ Generic Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class | Dossiers Status |
|---|---|---|---|---|---|---|---|
| 1 | Gabapentin Capsules | GABATAJ | Antiepileptic / Neuropathic Pain | Capsules | 100 mg, 200 mg, 300 mg, 400 mg | BCS Class II | Approved – Semi-Regulated Markets, Dossier Ready |
| 2 | Levetiracetam Tablets | LEVETAJ | Antiepileptic | Tablets | 250 mg, 500 mg, 750 mg, 1000 mg | BCS Class I | Approved – Semi-Regulated Markets, Dossier Ready |
| 3 | Colestipol Tablets | COLETAJ | Lipid Lowering Agent | Tablets | 1 g | BCS Class III | Approved – Semi-Regulated Markets, Dossier Ready |
| 4 | Diclofenac Potassium Tablets | DICLOTAJ-K | NSAID / Analgesic | Tablets | 50 mg | BCS Class II | Approved – Semi-Regulated Markets, Dossier Ready |
| 5 | Tizanidine Capsules | TIZATAJ | Muscle Relaxant | Capsules | 2 mg, 4 mg, 6 mg | BCS Class II | Approved – Semi-Regulated Markets, Dossier Ready |
| 6 | Desipramine Tablets | DESITAJ | Tricyclic Antidepressant | Tablets | 10 mg, 25 mg, 50 mg, 75 mg, 100 mg | BCS Class I | Approved – Semi-Regulated Markets, Dossier Ready |
| 7 | Isosorbide Mononitrate ER Tablets | ISOMONTAJ-ER | Antianginal | ER Tablets | 30 mg, 60 mg, 120 mg | BCS Class I | Approved – Semi-Regulated Markets, Dossier Ready |
| 8 | Pimozide Tablets USP | PIMOTAJ | Antipsychotic | Tablets | 1 mg, 2 mg | BCS Class II | Stability Charged Apr-2025, Dossier Ready |
| 9 | Avatrombopag Tablets | AVATROTAJ | Thrombopoietin Receptor Agonist | Tablets | 20 mg | BCS Class II | Stability Charged Apr-2025, Dossier Ready |
| 10 | Bismuth Subcitrate + Metronidazole + Tetracycline Capsules | BISMETTAJ | Anti-H. pylori Combination | Capsules | 140 mg / 125 mg / 125 mg | Mixed (II/III) | Stability Charged Jun-2025, Dossier Ready |
| 11 | Oxaprozin Capsules USP | OXAPTAJ | NSAID / Anti-Inflammatory | Capsules | 300 mg | BCS Class II | Stability Charged Aug-2025, Dossier Ready |
| 12 | Pyridostigmine Tablets | PYRITAJ | Cholinesterase Inhibitor | Tablets | 60 mg | BCS Class III | Stability Charged Sep-2025, Dossier Ready |
Dossiers by Q1–Q2 2026
| Sr. No. | Product Name | TAJ Generic Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class | Dossiers Status |
|---|---|---|---|---|---|---|---|
| 1 | Brivaracetam Tablets | BRIVATAJ | Antiepileptic | Tablets | 10 mg, 25 mg, 50 mg, 75 mg, 100 mg | BCS Class II | Stability Charging Jan-2026, Dossier Target Jan-26 |
| 2 | Edoxaban Tablets | EDOXATAJ | Anticoagulant (DOAC) | Tablets | 15 mg, 30 mg, 60 mg | BCS Class IV | Stability Charging Feb-2026, Dossier Target Mar-26 |
| 3 | Amlodipine + Atorvastatin Tablets | AMLOSTATTAJ | Antihypertensive + Lipid Lowering | Tablets | 5+10 mg, 5+20 mg, 5+40 mg, 5+80 mg, 10+10 mg, 10+20 mg, 10+40 mg, 10+80 mg | BCS Class II | Stability Charging Mar-2026, Dossier Target Apr-26 |
| 4 | Mesalamine Delayed Release Tablets | MESATAJ-DR | Anti-Inflammatory (IBD) | Delayed Release Tablets | 1.2 g | BCS Class IV | Stability Charging May-2026, Dossier Target Jun-26 |
Products under Development – Prototype Completed
| Sr. No. | Product Name | TAJ Generic Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class | Development Status |
|---|---|---|---|---|---|---|---|
| 1 | Methenamine Hippurate Tablets | METHETTAJ | Urinary Antiseptic | Tablets | 1 g | BCS Class I | EB Planned Q2-2026, Dossier Target Q4-2026 |
| 2 | Orlistat Capsules | ORLITAJ | Anti-Obesity | Capsules | 120 mg | BCS Class IV | Prototype Completed |
| 3 | Bempedoic Acid Tablets | BEMPETTAJ | Lipid Lowering Agent | Tablets | 180 mg | BCS Class II | Prototype Completed |
| 4 | Obeticholic Acid Tablets | OBETTAJ | Hepatobiliary Agent | Tablets | 5 mg, 10 mg | BCS Class II | Prototype Completed |
| 5 | Mitapivat Tablets | MITATAJ | Hematology (PK Deficiency) | Tablets | 5 mg, 20 mg, 50 mg | BCS Class II | Prototype Completed |
| 6 | Semaglutide Tablets | SEMATAJ | Antidiabetic (GLP-1) | Tablets | 1.5 mg, 3 mg, 4 mg, 7 mg, 9 mg, 14 mg | BCS Class III | Prototype Completed |
| 7 | Canagliflozin Tablets | CANATAJ | Antidiabetic (SGLT-2) | Tablets | 100 mg, 300 mg | BCS Class IV | Prototype Completed |
| 8 | Sacubitril + Valsartan Tablets | SACVALTAJ | Heart Failure Therapy | Tablets | 24/26 mg, 49/51 mg, 97/103 mg | BCS Class III | Prototype Completed |
| 9 | Tolvaptan Tablets | TOLVATAJ | Vasopressin Antagonist | Tablets | 15 mg, 30 mg, 45 mg, 60 mg, 90 mg | BCS Class III | Prototype Completed |
| 10 | Rivaroxaban Tablets | RIVATAJ | Anticoagulant (DOAC) | Tablets | 2.5 mg, 10 mg, 15 mg, 20 mg | BCS Class II | Prototype Completed |
| 11 | Acitretin Capsules | ACITTAJ | Dermatology (Retinoid) | Capsules | 10 mg, 25 mg | BCS Class II | Prototype Completed |
| 12 | Deferasirox Tablets | DEFERTAJ | Iron Chelator | Tablets | 90 mg, 180 mg, 360 mg | BCS Class II | Prototype Completed |
| 13 | Sucroferric Oxyhydroxide Chewable Tablets | SUCRATAJ | Phosphate Binder | Chewable Tablets | 500 mg | BCS Class III | Prototype Completed |
| 14 | Potassium Chloride ER Tablets | KCL-ERTA J | Electrolyte Supplement | ER Tablets | 600 mg, 750 mg, 1000 mg | BCS Class I | Prototype Completed |
Products under Literature Phase
| Sr. No. | Product Name | TAJ Generic Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class | Development Status |
|---|---|---|---|---|---|---|---|
| 1 | Resmetirom Tablets | RESMETAJ | Metabolic / NASH | Tablets | 60 mg, 80 mg, 100 mg | BCS Class II | EB Planned Q4-2026–Q1-2027, Dossier Target Q2–Q3-2027 |
| 2 | Cenobamate Tablets | CENOTAJ | Antiepileptic | Tablets | 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg | BCS Class II | Literature Phase |
| 3 | Finerenone Tablets | FINETTAJ | Cardiovascular / CKD | Tablets | 10 mg, 20 mg, 40 mg | BCS Class II | Literature Phase |
| 4 | Lumateperone Capsules | LUMATAJ | Atypical Antipsychotic | Capsules | 10.5 mg, 21 mg, 42 mg | BCS Class II | Literature Phase |
State-of-the-Art Manufacturing Facilities in India
Unit 1 – Sarigam Manufacturing Facility (Emerging Markets)
Our Sarigam unit is strategically designed to cater to emerging and semi-regulated markets, delivering flexibility, speed, and quality at scale.
- Certifications: WHO-GMP, DIGEMID Peru, ISO 9001:2015
- Regulatory Status: EU-GMP audit triggered and targeted for completion by FY 2026
- Dosage Forms: Tablets, capsules, oral liquids, powders
- Product Range: 500+ formulations across multiple therapeutic segments
This unit supports high-volume production with consistent quality, making it ideal for international tenders, institutional supplies, and private-label manufacturing.
Unit 2 – Viramgam Manufacturing Facility (Regulated Markets)
Our Viramgam facility is a flagship unit built to serve highly regulated global markets.
- Approvals: US-FDA, EU-GMP, UK-MHRA
- Current Capacity:
- 1.2 billion tablets per year
- 500 million capsules per year
- Expansion Ready Capacity:
- Up to 1.5 billion tablets
- 0.5 billion capsules
This facility is engineered for regulated market submissions, including US, UK, EU, and other stringent authorities, ensuring seamless compliance, audit readiness, and consistent supply.
Comprehensive Contract Manufacturing (CMO) Services
As a reliable Contract Manufacturing Organization (CMO) in India, we integrate seamlessly into our partners’ supply chains. Our CMO services are designed to ensure cost efficiency, regulatory compliance, and uninterrupted supply continuity.
Our CMO strengths include:
- End-to-end manufacturing of finished dosage forms
- Flexible batch sizes and scalable production
- Private label and branded generic manufacturing
- Full regulatory and quality documentation support
- Long-term manufacturing partnerships
We enable our partners to focus on marketing, distribution, and brand expansion, while we manage manufacturing with precision and accountability.
Advanced Contract Development & Manufacturing (CDMO) Capabilities
Our CDMO services are tailored for companies seeking an experienced partner for product development, technology transfer, and commercial manufacturing.
CDMO offerings include:
- Formulation development and optimization
- Process scale-up and validation
- Analytical method development
- Stability studies and lifecycle management
- Commercial manufacturing for global markets
With integrated development and manufacturing under one roof, we reduce timelines, minimize risk, and ensure smooth regulatory transitions.
Co-Development & In-Licensing Opportunities
At Stallion Labs, our innovation-driven arm, we actively pursue co-development and in-licensing collaborations. We partner with innovators, biotech companies, and formulation developers to jointly commercialize high-potential pharmaceutical products.
Collaboration models include:
- Shared development and commercialization strategies
- Regional and global in-licensing agreements
- Lifecycle management and line extensions
- Market-specific product customization
These partnerships are structured to create mutual value, faster market entry, and long-term sustainability.
Dedicated R&D Centre Driving Cost and Innovation
Our in-house R&D Centre, staffed by 25+ highly skilled scientists, plays a critical role in strengthening partner competitiveness. We focus on process efficiency, yield improvement, and formulation optimization to achieve measurable reductions in Cost of Goods Sold (COGS).
R&D capabilities include:
- Reverse engineering of complex generics
- Process optimization for high-yield manufacturing
- Excipient rationalization and cost control
- Continuous improvement for mature products
By combining scientific depth with commercial insight, we help partners enhance margins while maintaining uncompromised quality.
Extensive Generic Product Portfolio
Our generic pharmaceutical portfolio spans multiple therapeutic segments, including:
- Anti-infectives
- Cardiovascular medicines
- Central nervous system products
- Gastrointestinal therapies
- Pain management and anti-inflammatory drugs
- Nutraceuticals and wellness products
Each product is developed under strict quality-by-design (QbD) principles, ensuring reproducibility, safety, and global acceptance.
Why Global Partners Choose Taj Pharma
- 30+ years of proven manufacturing excellence
- Presence in 85+ countries worldwide
- US-FDA, EU-GMP, UK-MHRA approved facilities
- High-volume, scalable manufacturing capacity
- Strong focus on COGS reduction and efficiency
- Flexible CMO and CDMO engagement models
- End-to-end regulatory and documentation support
Our approach is built on trust, transparency, and long-term partnerships, enabling clients to scale confidently in competitive global markets.
Your Strategic Pharma Manufacturing Partner in India
As a leading generic pharma manufacturer in India, we continue to invest in infrastructure, talent, and technology to remain future-ready. Whether you seek a CMO partner, a CDMO solution provider, or a co-development collaborator, we deliver with consistency, compliance, and confidence.
We remain committed to advancing global healthcare by manufacturing medicines that meet international standards while staying commercially viable and accessible.
